Piper says it has learned that BMY has discontinued development of its early stage HCV protease inhibitor while saying it is no longer pursuing drug candidates in HCV. The development is seen as a clear positive for VRTX as investors believed the compound could have been a potentially serious competitor to VX-950.
From the fabulous folks at StreetAccount.com 7:38am Friday morning.
Market Data 
Markets 
AI
